SCHEMBL3763563

SCHEMBL3763563

NC(=O)c1ccc(C(F)(F)F)c(C(F)(F)F)c1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.43
BCAT2 O15382 1/20 0.42
KDM4E B2RXH2 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 2/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
PABPC1 P11940 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
PDK2 Q15119 1/20 0.38
IKBKB O14920 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ERN1 O75460 1/20 0.36
LMNA P02545 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4681806 0.83 BCAT2 (0.41) FABP4BCAT2KDM4EMEN1KMT2A
SCHEMBL5131382 0.83 KMT2A (0.46) BCAT2KDM4EMEN1KMT2APDK2
SCHEMBL27599997 0.81 FABP4 (0.46) FABP4BCAT2KDM4EMEN1KMT2A
SCHEMBL5314054 0.81 FABP4 (0.46) FABP4BCAT2KDM4EMEN1KMT2A
SCHEMBL4776531 0.81 FABP4 (0.46) FABP4BCAT2KDM4EMEN1KMT2A
SCHEMBL30339795 0.81 FABP4 (0.58) FABP4BCAT2GAANR1H2NR1H3
SCHEMBL530568 0.81 FABP4 (0.58) FABP4BCAT2GAANR1H2NR1H3
SCHEMBL27727318 0.81 BCAT2 (0.39) FABP4BCAT2KDM4EMEN1KMT2A
SCHEMBL28312107 0.80 IKBKB (0.49) NR1H2NR1H3IKBKBCHUK
SCHEMBL6173691 0.80 FABP4 (0.45) FABP4BCAT2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765736-B2 Benzenesulfonamide compounds and the use thereof PURDUE PHARMA L.P. (US) 2014-07-01 US disclosed
US-20100311792-A1 Benzenesulfonamide Compounds and the Use Thereof PURDUE PHARMA L.P. 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311792-A1 Benzenesulfonamide Compounds and the Use Thereof CACNA1A, CACNA1E, CACNA1B FABP4 3726/4885BCAT2 3018/4885KDM4E 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.